| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Tandem Diabetes Care (NASDAQ:TNDM) affirms FY2025 sales outlook from $1.000 billion to $1.000 billion vs $998.025 million estim...
Tandem Diabetes Care (NASDAQ:TNDM) reported quarterly losses of $(0.31) per share which met the analyst consensus estimate. Thi...
Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced it achie...
Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a global insulin delivery and diabetes technology company, announced that the t:slim ...
Dexcom faces new FDA reports linking its G7 glucose monitor to patient deaths as lawsuits and regulatory scrutiny intensify.
Stifel analyst Jonathan Block reinstates Tandem Diabetes Care (NASDAQ:TNDM) with a Hold and announces $15 price target.